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Abstract
Background: Transforming growth factor b (TGFb) receptor signaling is closely associated with the invasion ability
of gastric cancer cells. Although Smad signal is a critical integrator of TGFb receptor signaling transduction systems,
not much is known about the role of Smad2 expression in gastric carcinoma. The aim of the current study is to
clarify the role of phosphorylated Smad2 (p-Smad2) in gastric adenocarcinomas at advanced stages.
Methods: Immunohistochemical staining with anti-p-Smad2 was performed on paraffin-embedded specimens
from 135 patients with advanced gastric adenocarcinomas. We also evaluated the relationship between the
expression levels of p-Smad2 and clinicopathologic characteristics of patients with gastric adenocarcinomas.
Results: The p-Smad2 expression level was high in 63 (47%) of 135 gastric carcinomas. The p-Smad2 expression
level was significantly higher in diffuse type carcinoma (p = 0.007), tumours with peritoneal metastasis (p = 0.017),
and tumours with lymph node metastasis (p = 0.047). The prognosis for p-Smad2-high patients was significantly
(p = 0.035, log-rank) poorer than that of p-Smad2-low patients, while a multivariate analysis revealed that p-Smad2
expression was not an independence prognostic factor.
Conclusion: The expression of p-Smad2 is associated with malignant phenotype and poor prognosis in patients
with advanced gastric carcinoma.
Background
Transforming growth factor b (TGFb)i sam u l t i f u n c -
tional cytokine and one of most important pathways for
cancer cells [1,2]. TGFb binds to two different serine/
threonine kinase receptors (TbR), termed type I and
type II. The activated TbR type I kinase phosphorylates
Smad2 and Smad3. Phosphorylated Smad2 (p-Smad2)
and p-Smad3 are oligomerized with Smad4, migrate into
nucleus and regulate transcription [1,3]. In normal
epithelial cells, TGFb is a potent inhibitor of prolifera-
tion, and it has been considered a tumour suppressor.
Although TGFb acts as a tumour suppressor in early-
stage tumours, during tumour progression the TGFb
antiproliferative function is lost, and in certain cases
TGFb becomes an oncogenic factor inducing cell
proliferation, invasion, angiogenesis, and immune sup-
pression [4,5]. It has been reported that TGFb can signal
not only through Smad-dependent, but also Smad-
independent pathways [6]. Because of the dual aspects
of TGFb in oncogenesis, Smad signal might be a critical
integrator of TGFb receptor signaling transduction sys-
tems, although the significance of Smad expression is
still controversial. Bruna et al. 2007 demonstrated that
high TGFb-Smad activity is present in aggressive, highly
proliferative gliomas and confers poor prognosis in
patients with glioma [7], while a lack of Smad expres-
sion appears to be correlated with tumour development
and poor prognosis in patients with esophageal squa-
mous cell carcinoma [8] breast cancer [9] and colorectal
cancer [10]. Not much is known regarding the prognos-
tic value of Smad2 expression in gastric carcinoma,
while several reports of serum levels of TGFb [11,12]
suggested that TGFb can induce invasion and metastasis
in gastric carcinoma. Understanding the significance of
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therefore, we investigated the p-Smad2 expression of
gastric carcinoma to clarify the role of p-Smad2 in
advanced gastric adenocarcinomas.
Methods
Patients
We examined surgical samples from patients at the
Osaka City University Hospital, Osaka, Japan. A total of
135 patients who had undergone resection of primary
gastric tumours and were confirmed histologically to
have advanced gastric cancer, were enrolled in this
study. “Advanced cancer” indicates cancer invasion of
the muscularis propria or serosa. None of the patients
had undergone preoperative radiation or chemotherapy.
Pathological diagnoses and classifications followed the
Japanese Classification of Gastric Carcinoma [13]. Hepa-
tic metastasis and peritoneal metastasis were examined
at laparotomy. Peritoneal lavage cytology of the abdom-
inal cavity was performed at laparotomy, and exfoliated
cancer cells were microscopically examined. Depth of
tumour invasion, differentiation, lymph node metastasis,
venous invasion and lymphatic invasion were based on
microscopic examination of materials obtained by surgical
resection. The histological classification was based on the
predominant pattern of tumour. The histological subtypes
were: papillary adenocarcinoma, well-differentiated tubular
adenocarcinoma and moderately-differentiated tubular
adenocarcinoma, regarded as intestinal-type. The subtypes
were: solid poorly-differentiated adenocarcinoma, non-
solid poorly-differentiated adenocarcinoma, signet-ring
cell carcinoma and mucinous carcinoma, regarded as dif-
fuse-type. Lymph node metastasis was decided on the
regional lymph nodes metastasis. The regional lymph
nodes of the stomach are classified into three stations
numbered as described in the Japanese classification [13]
that depending upon the location of the primary tumour.
As the number of increase, it indicated that spread to dis-
tant lymph nodes. The study protocol conformed to the
ethical guidelines of the Declaration of Helsinki (1975).
This study was approved by the Osaka City University
ethics committee. Informed consent was obtained from all
patients prior to entry.
Immunohistochemical techniques
All the H&E-stained slides of the surgical specimens
were reviewed, and the representative section of the
tumour that included the site of deepest invasion was
selected for the immunohistochemical study.
A rabbit polyclonal anti-human P-Smad2 antibody
(Chemicon International, Themecula, CA. 1:2000) was
used to detect p-Smad2. The methods for immuno-
histochemical staining of p-Smad2 have been
described in the manufacturer’s instructions. In brief,
the slides were deparaffinized, and were heated for 20
min at 105°C by autoclave in Target Retrieval Solu-
tion (Dako, Carpinteria, CA). Sections were then
incubated with 3% hydrogen peroxide to block endo-
genous peroxidase activity. The specimens were incu-
bated with p-Smad2 antibody (1:2,000) overnight at 4°
C. The sections were incubated with biotinylated goat
anti-rabbit immunoglobulin G for 30 min, followed by
three washes with PBS. The slides were treated with
streptavidin-peroxidase reagent, and were incubated
in PBS diaminobenzidine and 1% hydrogen peroxide
v/v, followed by counterstaining with Mayer’s hema-
toxylin. We previously reported the expression level
of p-Smad2 in gastric cancer cell lines [14]. The
omission of the primary antibody served as negative
controls.
Immunohistochemical determination of p-Smad2
P-Smad2 staining was evaluated at the invasion front of
gastric cancers. Both hematoxylin and eosin staining
were used as a reference slide to select cancer areas at
the invading front. The existence of cancer cells was
continuously examined from the serosa to the mucosa
under a microscope. The invading front was determined
at the lesion where cancer cells were first found from
serosal side. P-Smad2 staining was evident in the nuclei
of cancer cells. The percentage of p-Smad2 immunopo-
sitive cells was determined by counting 3 areas ran-
domly chosen in the tissue in a total of 300 nuclei of
cancer cells. Evaluation was made by two double-
blinded independent observers who were unaware of
clinical data and histologic diagnoses. The percentage of
nucleus stained cells for p-Smad2 was also determined.
There were 15 (11%) cases of a discrepant evaluation
between the two independent observers. In those cases,
we rechecked and discussed and the final score was
obtained by consensus.
Staining was scored using the Allred scoring system as
described previously [15]. For semi-quantitative analysis
of p-Smad2 immuno-reactivity, the intensity of staining
and percentage of tumour stained cells were evaluated
in representative high-power (×400) and low-power
fields (×200) using optical microscopy: intensity was
scored 0-3 (0 = no immunoreactivity, 1 = weak, 2 =
moderate, and 3 = intense immunoreactivity) and pro-
portion was scored 0-5 (0 = 0%; 1 = 1-20%; 2 = 21-40%;
3 = 41-60%; 4 = 61-80%; 5 = 81-100%). The two scores
were then added to obtain the final result of 0-8. The
median score of all cases was 6.07. Then the cut-off
point was determined 6; p-Smad2 expression was con-
sidered high expression when scores were ≥7a n dl o w
expression when scores were <7.
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Comparative analyses of the data were performed using
t h eC h i - s q u a r et e s to rF i s h e r ’s exact test. The survival
durations were calculated using the Kaplan-Meier
method and analyzed by the log-rank test to compare the
cumulative survival durations in the patient groups. Cox
proportional-hazards regression was used to compute
univariate and multivariate hazards ratios for the study
parameters. A p-value of less than 0.05 was defined as
being statistically significant. SPSS 10.0 software (SPSS
Japan, Tokyo, Japan) was used for the analyses.
Results
Relationship between clinicopathological features and
phospho-Smad2 expression
Phospho-Smad2 was mainly immunolocalized in the
nuclei of cancer cells (Figure 1A). The intensity of stain-
ing and percentage of stained tumour cells were variable.
Regarding intensity, score 0 was found in no cases (0%),
score 1 in 55 cases (41%), score 2 in 33 cases (24%), and
score 3 in 47 (35%) cases. Upon evaluation of positive
cell percentages, score 0 was found in no cases (0%),
score 1 in 2 cases (1%), score 2 in 11 cases (8%), score 3
in 16 cases (12%), score 4 in 43 cases (32%), and score 5
in 63 cases (47%). The total Allred scores varied from 2
to 8. The high expression level of p-Smad2 was found in
63 (47%) of 135 gastric carcinomas. The relationships
between p-Smad2 expression and clinicopathological fea-
tures of the tumours are shown in Table 1. P-Smad2
expression level was significantly high in diffuse type car-
cinoma (p = 0.011) and significantly correlated with peri-
toneal metastasis (p = 0.017), lymph node metastasis by
Japanese classification [13] or UICC classification [16]
(p = 0.047, p = 0.004) and peritoneal cytology (p = 0.026).
“Peritoneal cytology” means peritoneal lavage cytology at
laparotomy as a standard method for the detection of
free tumor cells and a useful predictor of peritoneal
recurrence in gastric cancer. In 12 cases, peritoneal cytol-
ogy was not performed. Then the total number of perito-
neal cytology was 123 cases. There was no statistically
significant association between the phospho-Smad2
expression and either hepatic metastasis, venous invasion
or lymphatic invasion. The number of metastatic lymph
nodes in high-expression group (median = 12.3) was sig-
nificantly (p = 0.002) higher than that in low-expression
group (median = 5.77), while no difference of the number
of affected lymph nodes was shown between low-p-
Smad2 groups (median = 41.1) and high-p-Smad2 groups
(median = 44.4).
Phospho-Smad2 relates with poor prognosis in
gastric cancer
In this series of advanced gastric cancer, survival of
phospho-Smad2 high level expression patients was
significantly poorer than that of phospho-Smad2 low
level expression patients (p = 0.035, Figure 1B). In uni-
variate analysis, high phospho-Smad2 expression (p =
0.048), morphological type 4 (p < 0.001), diffuse-type
tumours (p < 0.001), lymph node metastasis (p < 0.001),
peritoneal metastasis (p < 0.001), peritoneal free cancer
cells (p < 0.001), lymphatic invasion (p = 0.006) and
clinical stage IV (p < 0.001) were significantly associated
to poor patient survival (Table 2). In multivariate analy-
sis, morphologic type 4, diffuse-type tumours and clini-
cal stage IV were statistically independent prognostic
factors, but phospho-Smad2 was not (Table 3).
Discussion
P-Smads2 is a primary step and intracellular signaling
effector for the mediation of intracellular signaling of
TGFb [1]. In early-stage tumours TGFb acts as a
tumours suppressor, while in advanced tumours it
becomes an oncogenic factor. Because of the dual role
of TGFb in oncogenesis, depending on the type and
stage of the tumour, we focused our study on p-Smad2
expression on the advanced stage of gastric cancer. P-
Smad2 expression levels of cancer cells were high in 63
(47%) of 135 gastric carcinomas, suggesting that some
types of gastric carcinomas were strongly-affected by
TGFb. In the present study, p-Smad2 expression in
tumour cells was significantly higher in diffuse-type
tumours and in cases with peritoneal metastasis, free
peritoneal cancer cells and lymph node metastasis.
Moreover, p-Smad2 high expression predicted poor sur-
vival. These findings suggest that p-Smad2 is associated
to malignant phenotype and is a molecular biomarker of
disease outcome in advanced gastric cancer.
P-Smad2 expression levels of cancer cells were high in
diffuse-type gastric carcinoma also known as a scirrhous
type. There are two types of gastric cancer: diffuse type
and intestinal type, according to the Laurén classifica-
tion [17]. The characteristic clinical features of diffuse-
type gastric carcinoma, a diffusely infiltrating type of
gastric carcinoma, include a high frequency of metasta-
sis to the LNs [18-20] and to the peritoneum [21-23].
The expression level of TGFb in scirrhous gastric carci-
noma was related with poor prognosis [24]. Tumor cells
in scirrhous carcinoma produce more TGFb than non-
scirrhous carcinoma [25,26]. TGFb signals might play an
important role for the metastatic spread of cancer cells
such as migration, and invasion, as previously reported
[2,11,27]. In fact, Overexpression of Smad2 was asso-
ciated with metastasis, and was correlated with poor
prognosis of gastric tumors especially diffuse-type gas-
tric carcinoma. TGFb-Smad2 signaling may have an
important role in the progression of diffuse-type gastric
carcinoma. The activated Smad2 level might be
associated with the different clinical phenotype of
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Figure 1 (A), Immunohistochemical determination of p-Smad2. P-Smad2 was found in the nuclei of cancer cells. The Immunoreactive
intensity score of p-Smad2 staining in tumour cells was evaluated using the positive and negative controls. Score 3 means high intensity as
same as the positive control. Immunoreactivity, score 1 = weak, score 2 = moderate, and score 3 = intense. (×400). (B), The overall survival of
patients based on p-Smad2 expression. The Kaplan-Meier survival curve shows the overall survival in relation to the p-Smad2 expression in 135
patients with gastric carcinoma. A statistically significant difference in the survival was observed between the high p-Smad2 groups and low
p-Smad2 groups (p = 0.035; log-rank,).
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Page 4 of 8Table 1 Relationships between p-Smad2 and clinicopathological features in 135 gastric cancer cases
Parameter P-Smad2 p-Value
High (n = 63) Low (n = 72)
Gender
Male 39 (41.9%) 54 (58.1%) N.S.
Female 24 (57.1%) 18 (42.9%)
Morphologic feature
+
Type 1 6 (37.5%) 10 (62.5%) 0.025
Type 2 14 (35.0%) 26 (65.0%)
Type 3 17 (45.9%) 20 (54.1%)
Type 4 26 (61.9%) 16 (38.1%)
T stage
2 7 (25.9%) 20 (74.1%) 0.031
3 52 (50.0%) 52 (50.0%)
4 4 (100.0%) 0 (0.00%)
Differentiation
Intestinal-type 15 (31.2%) 33 (68.8%) 0.011
Diffuse-type 48 (55.2%) 39 (44.8%)
Lymph node metastasis
+
(Japanese classification)
N0 and N1 34 (40.5%) 50 (59.5%) 0.047
N2 and N3 29 (56.9%) 22 (43.1%)
Lymph node metastasis
++
(UICC classification)
N0 and N1 31 (36.9%) 53 (63.1%) 0.004
N2 and N3 32 (62.7%) 19 (37.3%)
Hepatic metastasis
Negative 62 (47.0%) 70 (53.0%) N.S.
Positive 1 (33.3%) 2 (66.7%)
Peritoneal metastasis
Negative 48 (42.1%) 66 (57.9%) 0.017
Positive 15 (71.4%) 6 (28.6%)
Peritoneal cytology
+++
Negative 36 (40.4%) 53 (59.6%) 0.026
Positive 22 (64.7%) 12 (35.3%)
Lymphatic invasion
Ly0 and ly1 26 (40.6%) 38 (59.4%) N.S.
Ly2 and ly3 37 (52.1%) 34 (47.9%)
Venous invasion
Negative 50 (45.5%) 60 (54.5%) N.S.
Positive 13 (52.0%) 12 (48.0%)
Clinical stage
I 2 (22.2%) 7 (77.8%) 0.022
II 15 (39.5%) 23 (60.5%)
III 18 (40.0%) 27 (60.0%)
IV 28 (68.7%) 15 (31.3%)
+, Classification according to the General Rules for Gastric Cancer Study of the Japanese Research Society for Gastric Cancer [13]. Type 1 is defined as a polypoid
tumor; type 2 as polypoid tumor with ulceration and with sharply demarcated margins; type 3 as ulcerated carcinoma with cancer infiltration into the
surrounding wall; type 4 as diffusely infiltrating flat carcinoma in which ulceration is usually not a marked feature.
++, Nodal stage was assessed by the Union Internationale Contre le Cancer (UICC) tumor node metastasis (TNM) classification [16] and by classification according
to the general rules for gastric cancer study of the Japanese Research Society for Gastric Cancer. In the TNM classification, nodal stage was classified according to
the number of involved regional LNs as follows: pN0, no LN spread; pN1, 1 to 6 diseased LNs; pN2, 7 to 15; and pN3, more than 15. In the Japanese
classification, nodal stage was classified according to the extent of positive LN into n0, n1, n2, and n3 and is considered to reflect the anatomic pathway of
lymphatic spread. n1 is defined as proximate regional LN disease, and n2 or n3 are defined as distant.
+++, In 12 cases, peritoneal cytology was not performed (Total 123 cases).
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Page 5 of 8malignancy between the diffuse-type and intestinal-type
in gastric carcinoma.
Immunohistochemical is a good method of choice for
the evaluation of protein expression within a particular
tissue, since it is possible to distinguish the cell types
stained, as well as the number of cells and intensity of
the immunohistochemical stained. Both analyses must
be combined and it was done. Allred score system eval-
uates a combination of intensity and proportion, poten-
tially increasing the prognostic value of the analysis by
the intensity alone or the proportion alone in this study.
Allred scores of 7-8 were considered suitable for the
identification of aggressive advanced gastric carcinoma.
Allred score system for p-Smad2 expression might be
suitable for accurately assessing p-Smad2-expressing
tumor cells, and might be adequate for predicting the
outcome of patients with gastric cancer. P-Smad2 stain-
ing was evaluated at the invasion front of gastric can-
cers. P-Smad2 expression in nuclei of cancer cells was
continuously examined from the serosa to the mucosa
under a microscope. Few difference of p-Smad2 staining
was found between infiltrative front and surface lesions
in the same cases. And, the tumor cells at the invading
front might play an important role for distant metasta-
sis. Therefore, p-Smad2 expression of the tumor cells
was evaluated at the invading front.
Since the activated Smad2 was associated with the
malignant phenotype of gastric cancer, it is possible that
inhibition of p-Smad2 signaling in gastric carcinoma
may yield beneficial effects through inhibition of inva-
sion and metastasis of cancer. Although, the TGFb path-
way is being evaluated as a therapeutic target in gastric
Table 2 Univariate analysis with respect to overall survival (n = 135)
Parameter Risk ratio 95% Confidence interval p-Value
P-Smad2 expression 1.650 1.005–2.710 0.048
Low vs. high
Morphologic feature 5.354 3.199–8.963 <0.001
Type 1, 2, and 3 vs. type 4
Differentiation 3.883 2.020–7.463 <0.001
Intestinal-type vs. Diffuse-type
Lymph node metastasis (Japanese classification) 3.269 1.978–5.403 <0.001
N0 and N1 vs. N2 and N3
Peritoneal dissemination 5.534 3.056–8.738 <0.001
Negative vs. positive
Peritoneal cytology 5.937 3.468–10.166 <0.001
Negative vs. positive
Lymphatic invasion 2.055 1.234–3.421 0.006
Ly0 and ly1 vs. ly2 and ly3
Clinical Stage 6.901 4.088–11.651 <0.001
I, II, and III vs.I V
Table 3 Multivariate analysis with respect to overall survival (n = 135)
Parameter Risk ratio 95% Confidence interval p-Value
P-Smad2 expression 0.627 0.347–1.133 0.122
Low vs. high
Morphologic feature 2.325 1.221–4.388 0.010
Type 1, 2, and 3 vs. type 4
Differentiation 2.807 1.251–6.298 0.012
Intestinal-type vs. Diffuse-type
Lymph node metastasis (Japanese classification) 1.387 0.689–2.794 0.360
N0 and N1 vs. N2 and N3
Peritoneal dissemination 1.097 0.549–2.193 0.793
Negative vs. positive
Lymphatic invasion 1.394 0.805–2.413 0.235
Ly0 and ly1 vs. ly2 and ly3
Clinical Stage 4.382 1.924–9.978 <0.001
I, II, and III vs.I V
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Page 6 of 8cancer [28,29], the complex roles of TGFb in tumor
progression might make it difficult to select the patients
that will benefit from an anti-TGFb therapy. The deter-
mination of p-Smad2 expression by the Allred score sys-
tem might improve patient selection and the
development of successful targeted therapies, although it
will be necessary to confirm that the p-Smad2 Allred
score also provides significant prognostic power for gas-
tric cancer patients in a prospective study.
Conclusion
P-Smad2 appears to play a crucial role in advanced gas-
t r i cc a r c i n o m aa n dm a yb eau s e f u lp r o g n o s t i cm a r k e r
of poor prognosis.
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